Fig. 5.

Proteoglycan synthesis and content following RARγ over-expression and inverse agonist treatment.

(A-B) Proteoglycan synthesis in control and RARβ/RARγ-deficient chondrocyte cultures over-expressing RARγ (pCMV-HA-RARγ) or following treatment with inverse agonist. (C-H) Phase microscopic appearance of control and RARβ/RARγ-deficient chondrocytes in untreated control cultures (None) and in companion cultures treated with 300 nM retinoic acid (RA) or 100 nM inverse agonist (INV). (I-L) Alcian blue staining of control and RARβ/RARγ-deficient cultures treated for 6 days with inverse agonist, RA or a RARγ-selective agonist. Consistency of results was established in three independent experiments.